FBLG — FibroBiologics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1958777 ·
Last close
$0.92
Market Cap
$4.78M
52W High
$1.83
52W Low
$0.73
ADV30
166,749
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,068,000 | -5,000,000 | 5,938,000 | 1,482,000 | 3,338,000 |
| Dec 2025 | 0 | — | -2,590,000 | -3,244,000 | 9,619,000 | 4,894,000 | 3,463,000 |
| Sep 2025 | 0 | — | -5,038,000 | -5,778,000 | 8,744,000 | 4,867,000 | 8,619,000 |
| Jun 2025 | 0 | — | -4,490,000 | -4,658,000 | 13,907,000 | 8,845,000 | 13,047,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,483,000
Investing CF
$-219,000
Financing CF
$8,517,000
CapEx
$-361,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.04
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-59,164,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-18,472,000
Pretax Income TTM
$-18,680,000
Interest Exp TTM
$208,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,649,000 | -18,646,000 | 9,619,000 | 3,463,000 | — | -16,394,000 |
| Dec 2024 | 0 | -13,737,000 | -11,161,000 | 16,445,000 | 13,710,000 | — | -11,901,000 |
| Dec 2023 | 0 | -8,889,000 | -16,485,000 | 11,821,000 | 10,568,000 | — | -6,401,000 |
| Dec 2022 | 0 | -4,467,000 | -5,121,000 | 4,824,000 | 8,820,000 | — | -4,066,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBIO | MUSTANG BIO, INC. | $4.74M | $0.70 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $4.84M | $0.76 | — |
| APVO | Aptevo Therapeutics Inc. | $4.91M | $3.94 | — |
| INBP | INTEGRATED BIOPHARMA INC | $4.97M | $0.16 | — |
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $4.57M | $2.61 | — |
News headlines (Yahoo Finance, 1h cache)
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
2026-07-09 12:30 · Yahoo
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
2026-07-07 12:30 · Yahoo
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-30 12:30 · Yahoo
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2026-06-29 20:01 · Yahoo
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2026-06-26 12:30 · Yahoo
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
2026-06-22 12:30 · Yahoo
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
2026-06-16 12:30 · Yahoo
FBLG: Phase 1/2 Trial of CYWC628 Underway
2026-06-04 10:02 · Yahoo
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
2026-06-03 11:00 · Yahoo
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
2026-06-03 10:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.